{"id":10815,"date":"2016-02-03T16:26:56","date_gmt":"2016-02-03T09:26:56","guid":{"rendered":"https:\/\/www.biotec.or.th\/home\/?p=10815"},"modified":"2020-10-07T22:46:37","modified_gmt":"2020-10-07T15:46:37","slug":"anti-malarial-p218-shows-promising-result-in-the-preclinical-study","status":"publish","type":"post","link":"https:\/\/www.biotec.or.th\/home\/en\/anti-malarial-p218-shows-promising-result-in-the-preclinical-study\/","title":{"rendered":"Anti-malarial P218 shows promising result in the preclinical study"},"content":{"rendered":"\n<p>Discovered by BIOTEC research team together with the Medicines for Malaria Venture (MMV), the patented P218 compound was designed based-on 3-dimensional structures of malaria protein target, dihydrofolate reductase, in order to circumvent mutations that had led to resistance to pyrimethamine, a safe and previously effective drug for the treatment of malaria. Preclinical assessment of P218 compound under GLP standard was made in 2014-2015 under the collaboration between NSTDA and MMV. The results showed satisfactory safety profiles across a panel of required toxicology package in both in vitro and animal models (rodent and dog models) to demonstrate feasibility for First-in-Human (FIH) study.<\/p>\n\n\n\n<figure class=\"wp-block-image\"><img decoding=\"async\" src=\"http:\/\/www.biotec.or.th\/en\/images\/stories\/News\/2016\/Anti-Malarial_P218\/649592.jpg\" alt=\"649592\"\/><\/figure>\n\n\n\n<p>P218 is the work of researchers from BIOTEC Protein-Ligand Engineering and Molecular Biology Laboratory. In developing anti-malarial drug, the team focuses mainly on two drug targets in folate metabolism, dihydrofolate reductase (DHFR) and dihydropteroate synthase (DHPS). For more information, please visit this&nbsp;<a href=\"http:\/\/www.biotec.or.th\/proteineng\/\" target=\"_blank\" rel=\"noreferrer noopener\">website<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Discovered by BIOTEC research team together with the Medicines for Malaria Venture (MMV), the patented P218 compound was designed based-on 3-dimensional structures of malaria protein target, dihydrofolate reductase, in order to circumvent mutations that had led to resistance to pyrimethamine, [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":15400,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_wp_rev_ctl_limit":""},"categories":[33],"tags":[],"class_list":["post-10815","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/www.biotec.or.th\/home\/wp-json\/wp\/v2\/posts\/10815","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.biotec.or.th\/home\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.biotec.or.th\/home\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.biotec.or.th\/home\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.biotec.or.th\/home\/wp-json\/wp\/v2\/comments?post=10815"}],"version-history":[{"count":0,"href":"https:\/\/www.biotec.or.th\/home\/wp-json\/wp\/v2\/posts\/10815\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.biotec.or.th\/home\/wp-json\/wp\/v2\/media\/15400"}],"wp:attachment":[{"href":"https:\/\/www.biotec.or.th\/home\/wp-json\/wp\/v2\/media?parent=10815"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.biotec.or.th\/home\/wp-json\/wp\/v2\/categories?post=10815"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.biotec.or.th\/home\/wp-json\/wp\/v2\/tags?post=10815"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}